HWAM
TSHA icon

Hennion & Walsh Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Hennion & Walsh Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.61M Buy
536,739
+17,619
+3% +$102K 0.08% 312
2026
Q2 		$3.54M Buy
519,120
+127,644
+33% +$755K 0.1% 253
2026
Q1 		$1.75M Buy
391,476
+83,019
+27% +$386K 0.06% 381
2025
Q4 		$1.7M Buy
+308,457
New +$1.5M 0.06% 394

Other funds holding TSHA

WN
Williams & Novak Westlake Village, California $169M AUM 17.63% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Hennion & Walsh Asset Management's TSHA Position: Q3 2026 in Review

Hennion & Walsh Asset Management increased its Taysha Gene Therapies (TSHA) stake by 3.4% in Q3 2026, buying an estimated $102K and bringing the position to 536,739 shares worth $2.61M. The position accounts for 0.08% of the portfolio, ranked #312.

Hennion & Walsh Asset Management first reported a position in TSHA in Q4 2025 and has held it in 4 quarters since. The position peaked at $3.54M in Q2 2026. 7 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Hennion & Walsh Asset Management held 536,739 shares of Taysha Gene Therapies worth $2.61M as of Q3 2026.
  • Hennion & Walsh Asset Management bought 17,619 Taysha Gene Therapies shares in Q3 2026, an estimated $102K.
  • Taysha Gene Therapies made up 0.08% of Hennion & Walsh Asset Management's portfolio in Q3 2026, its #312 holding.
  • Hennion & Walsh Asset Management first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 4 quarters since.
  • Hennion & Walsh Asset Management's Taysha Gene Therapies position peaked at $3.54M in Q2 2026.
  • 7 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q3 2026, filed 13 Oct 2026.